Hepatocellular cancers (HCC) are highly resistant to chemotherapy. TGFb has been associated with chemoresistance in some human cancers but the mechanisms involved are unknown. We explored how TGFb might contribute to altered responses to therapy by assessing the involvement and mechanistic contribution of extracellular vesicle long non-coding RNA (lncRNA) in mediating TGFbdependent chemoresistance. TGFb reduced the sensitivity of HCC cells to sorafenib or doxorubicin and altered the release of both extracellular vesicles and of selected lncRNA within these vesicles. Amongst these, lincRNA-ROR (linc-ROR), a stress-responsive lncRNA was highly expressed in HCC cells and enriched within extracellular vesicles derived from tumor cells. Incubation with HCCderived extracellular vesicles increased linc-ROR expression and reduced chemotherapy-induced cell death in recipient cells. Sorafenib increased linc-ROR expression in both tumor cells and extracellular vesicles, whereas siRNA to linc-ROR increased chemotherapy-induced apoptosis and cytotoxicity. Tumor-initiating cells that express CD133 have an increased resistance to therapy. TGFb increased expression of CD133+ cells and colony growth in limiting dilution assays, both of which were attenuated by linc-ROR knockdown. These data provide mechanistic insights into primary chemoresistance in HCC by showing that: (a) TGFb selectively enriches linc-RoR within extracellular vesicles, which has a potential role in intercellular signaling in response to TGFb; (b) expression and enrichment of linc-ROR during chemotherapeutic stress plays a functional role in chemoresistance; and (c) the effects of TGFb on chemoresistance in HCC may involve linc-RoR-dependent effects on tumor-initiating cells. These findings implicate extracellular vesicle lncRNA as mediators of the chemotherapeutic response, and support targeting linc-ROR to enhance chemosensitivity in HCC.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality [1] . These cancers are highly chemoresistant. Although a large number of therapeutic agents have been evaluated for the treatment of HCC, most have been ineffective. Sorafenib and doxorubicin are currently used for systemic or locoregional therapies for HCC but have limited efficacy [2, 3] . The heterogeneous nature of HCC and the lack of targetable oncogenic driver mutations further limit the effectiveness of targeted therapies. The poor prognosis of unresectable HCC is related to the highly chemoresistant nature of this cancer [4] . Understanding the mechanisms contributing to innate or acquired resistance to therapy in HCC is therefore necessary and essential in order to develop more effective treatments.
Cellular toxicity and stress occurring during exposure to therapeutic agents such as sorafenib can elicit survival responses that eventually result in resistance to these agents. Within the liver, injury results in activation of mesenchymal cells with release of soluble mediators such as transforming growth factor b (TGFb) [5, 6] . TGFb is a central contributor to hepatic fibrosis and has been implicated to contribute to hepatocarcinogenesis through diverse mechanisms. TGF-b can modulate the expression of genes relevant to tumor development and promote malignant transformation of progenitor cells, and thereby link hepatic injury, fibrotic responses and cancer [7] [8] [9] [10] . Although TGFb has been associated with chemoresistance in human cancers [11] , the mechanisms remain unknown.
We postulated that TGFb enhances local environmental changes and cellular reprogramming that facilitate chemoresistance. We have recently shown that HCC cells can release extracellular vesicles (EVs) such as exosomes [12] . These vesicles contain protein, lipids and RNA derived from their donor cell cytoplasm and can be taken up by other cells. The intercellular transfer of EV contents thus provides a mechanism by which cells can communicate with other cells in their local microenvironment. The presence of mRNA and non-coding RNA within EV is of particular interest because these RNA molecules can modulate gene expression and cellular activities in recipient cells [13] [14] [15] [16] . Based on our previous findings that HCC cell derived EVs contain miRNAs that can modulate transformed cell behavior in target cells [12] , we hypothesized that intercellular signaling by EV RNA in response to TGFb could mediate chemoresistance. Our studies evaluated the role of EV signaling in tumor cell responses to TGFb and identified EV long non-coding RNA signaling mediators involved in modulation of cellular responses to chemotherapy. These findings provide several new mechanistic insights into acquired chemoresistance in HCC, and identify mediators and mechanisms that could be targeted to /well) in a 96 well plate and incubated with 0 or 10 ng/ml of TGFb for 24 h. Cells were then exposed to 1 or 2.5 lM sorafenib for 6 h. Caspase-3/7 activity was assessed using a commercial luminometric assay. Data were expressed relative to luminescence values of 1 lM sorafenib without TGFb. Data represents the means ± standard error of the mean (SEM) of 3 separate studies, with each study conducted in quadruplicate. 
Materials and methods

Cell lines, culture, and reagents
HepG2 and PLC-PRF5 cells were obtained from American Type Culture Collection (Manassas, VA), and cultured in DMEM high glucose medium (HyClone Laboratories, Logan, UT), containing 10% fetal bovine serum and 1% antibiotic-antimycotic (Invitrogen, Grand Island, NY), at 37°C with 5% CO2. Non-malignant human hepatocytes HH were obtained from Sciencell and cultured as recommended by the supplier. For all studies with extracellular vesicles, vesicle depleted medium was prepared by centrifuging cell-culture medium at 100,000g overnight to spin down any pre-existing vesicle content. Camptothecin and doxorubicin were obtained from Sigma-Aldrich (St. Louis, MO), and sorafenib was obtained from Selleck (Houston, TX). Compounds were dissolved in 100% DMSO (Sigma-Aldrich, St. Louis, MO) and diluted with culture media to the desired concentration with a final DMSO concentration of 0.1%. DMSO 0.1% (v/v) was used as a solvent control.
Isolation of EV
EV were isolated from HCC cells as previously described [17] . Cells (1 Â 10 6 ) were plated in vesicle-depleted medium, and medium was collected after 3-4 days for EV isolation for EV isolation by sequential centrifugation. Each isolation was verified using nanoparticle tracking analysis using a Nanosight N-300 (NanoSight Ltd., Amesbury, UK) to determine size and quantity of EV isolated. Isolated EVs were used immediately, or were resuspended in 50-100 ll of PBS and stored at À80°C.
RNA extraction and analysis
Total RNA was extracted from cells using Trizol (Invitrogen) or from EV using ExoQuick-TC (System Biosciences, Mountain View, CA). HepG2 cells (1 Â 10 6 ) were plated in 11 ml of EV-depleted medium on collagen-coated 10-cm dishes. After 3-4 days, the medium was collected and sequentially centrifuged at 3000Âg for 15 min to remove cells and cell debris. The supernatant was transferred to a sterile vessel and combined with 2 ml ExoQuick-TC. After an overnight precipitation at 4°C, total RNA was extracted using SeraMir™ Exosome RNA Amplification Kit (System Biosciences, Mountain View, CA) according to the manufacturers' instructions. RNA concentration was measured using NanoDrop ND-2000 (Nano-Drop Technologies, Wilmington, DE).
Real-time PCR analysis
RNA was treated with RNase-free DNase I (Qiagen, Valencia, CA). One microgram of RNA was reverse-transcribed to cDNA using iScript cDNA Synthesis Kit (BIO-RAD Laboratories, Inc., Hercules, CA), and Real-time quantitative RT-PCR (qRT-PCR) was performed using a Mx3000p System (Stratagene, La Jolla, CA) to detect RNU6B (U6) and lincRNA-ROR using SYBR green I (SYBR Ò Advantage Ò qPCR Premix, Clontech., Mountain View, CA). The following PCR primers were used: lincRNA-ROR primers, forward:
Gene expression profiling
The expression of 90 lncRNA was performed using the LncProfiler™ qPCR Array Kit (System Biosciences, Mountain View, CA). RNA from EV or donor cells (n = 3 per each cell line) were treated with DNase I and 2 lg of DNase-treated RNA was reverse transcribed. Real-time PCR was performed (2X Maxima Ò SYBR Green with Rox, Fermentas, Glen Burnie, MD) and the cycle number at which the reaction crossed a threshold (CT) was determined for each gene. Raw CT values were normalized using a median CT value (DCT = CT lncRNA À CT median ). The relative amount of each lncRNA in HCC cells relative to nonmalignant hepatocyte (fold change) was described using the equation qPCR Master Mix, Qiagen, Valencia, CA) and mRNA expression levels were evaluated using a comparative CT method.
Transfection of siRNAs
Two different siRNA against linc-RoR (5 0 to 3 0 ); siRNA linc-ROR-1: GGAGAGGAAGCCTGAGAGT, and siRNA linc-ROR-2: GGTTAAAG ACACA-GGGGAA as well as a non-targeting (NT) control siRNA (siGENOME Non-Targeting siRNA) were purchased from Dharmacon (Lafayette, CO). Validated siRNA to p53 siRNA were obtained from Life Technologies (Grand Island, NY). Cell transfections were performed using 50-100 nM siRNA using Lipofectamine 2000 (Life Technologies, Grand Island, NY).
Luciferase assay
Cells were co-transfected with p53-Luc Plasmid (Agilent Technologies, Santa Clara, CA) and pRL-TK Renilla Vector (Promega, Madison, WI) using Lipofectamine 2000 (Life Technologies, Grand Island, NY). After 24 h, total cell extracts were assayed for luciferase activity using Dual-Luciferase Ò Reporter Assay System (Promega), and a multiwell plate luminometer (Turner Biosystems, Sunnyvale, CA) according to the manufacturer's instruction.
Chemosensitivity assays
For studies of chemotherapeutic stress, cells were incubated with varying concentrations of sorafenib, camptothecin, doxorubicin or the appropriate diluent (DMSO) control for 72 h. Cells were seeded (1 Â 10 4 /well) in collagen-coated 24-well or 96-well plates. Cell viability was assessed by microscopy after staining with trypan blue and the number of viable cells expressed relative to cell /well) on 96 well plates and treated with (A) sorafenib, (B) doxorubicin or (C) camptothecin at the indicated concentrations. The number of viable cells was counted after 48 h using a hemocytometer after trypan blue staining. Bars express the mean value ± SEM of 3 separate determinants.
⁄ p < 0.05.
counts at baseline. Inhibition of proliferation was assessed using a CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay Kit MTS assay (Promega) and a FLUOstar Omega Microplate Reader (BMG Labtech, Cary, NC). Proliferation index was expressed as a percentage of absorbance values in experimental conditions compared to that for control cells.
Caspase 3/7 activity assay
Cells were seeded (1 Â 10 4 /well) into 96-well collagen-coated plates in appropriate media and incubated for 24 h. Then medium was then replaced with medium containing different concentrations of sorafenib. At selected time points, caspase-3/7 activity was assessed using Caspase-GloR3/7 Assay kit (Promega, Madison, WI) using a FLUOstar Omega Microplate Reader (BMG Labtech, Cary NC). Data were expressed as relative luminescence values relative to those of controls without chemical substance.
Flow cytometry
Flow cytometry was performed using an Accuri C6 flow cytometer (Accuri, Ann Arbor, MI). For cell cycle analysis, cells were permeabilized with 70% ethanol, and DNA was stained with 20 lg/ml were stained with annexin V-FITC or propidium iodide (Clontech, Mountain View, CA), and the proportion of cells undergoing apoptotic death was quantitated. For CD133+ and EpCAM expression, cells were incubated with CD133/1 (AC133) pure mouse monoclonal antibody (Miltenyi Biotec, Cambridge, MA), mouse monoclonal (AUA1) antibody to EPCAM (Abcam, Cambridge, MA) or IgG1 (normal mouse IgG1 antibody, Santa Cruz, Dallas, Texas) as an isotype control, and then with goat-anti-mouse IgG1-FITC (Santa Cruz, Dallas, Texas).
In vitro limiting dilution assay
Self renewal capacity was assessed using spheroid formation assays. Single cell suspensions were seeded (100 to 2000 / well) in ultra-low attachment surface 96-well plates (Corning, Corning, NY). Each well was supplemented with 100 ll of serum-free DMEM medium or DMEM medium containing 1% FBS. The number of spheroids was examined under a light microscope after 7 days. The total number of wells containing spheroids was determined. Twelve replicates were used for each condition and the percentage of total cultures which yield positive spheroid (proportion) was analyzed using L-Calc software (StemCell Technologies, Vancouver, BC, Canada) based on Poisson distribution.
Statistical analysis
Data were expressed as the mean and standard error from at least four replicates unless noted otherwise. Comparisons between groups were performed using the two-tailed Student's t test, and results were considered to be statistically significant when p < 0.05.
Results
Does TGFb modulate chemotherapy resistance and increase EV release?
Innate or acquired resistance to therapy is a hallmark of hepatocellular cancers. In order to explore therapeutic strategies to enhance chemotherapeutic responses, or to reduce the potential for acquired resistance, we investigated the effects and mechanisms by which TGFb could modulate responses of hepatocellular cancer to therapy. Exogenous exposure of HepG2 or PLC-PRF5 cells to TGFb did not significantly alter the growth of either HepG2 or PLC-PRF5 HCC cells. These cells were sensitive to sorafenib (IC50 of 2.8 lM in HepG2 cells and 2.4 lM in PLC-PRF5 cells) as well as to doxorubicin (IC50 of 22 nM in HepG2 cells and 0.9 lM for PLC-PRF5 cells). TGFb ameliorated growth inhibition with either agent, with similar effects observed in both of the cell lines (Fig. 1A) . Furthermore, TGFb reduced sorafenib induced caspase 3/7 activity, consistent with a reduction in apoptosis (Fig. 1B) . Although TGFb has been reported to have divergent roles in cancers, these data are consistent with those from other malignancies such as colorectal cancer, breast and ovarian cancers in which TGFb has been implicated in chemoresistance [18] . 
Can intercellular transfer of extracellular vesicles (EVs) modulate chemoresistance?
To ascertain if inter-cellular signaling by EV could modulate responses to chemotherapy, we first isolated EV from HepG2 cells in culture and characterized them using electron microscopy, sedimentation characteristics and size quantitation using nanoparticle tracking analysis using Nanosight (Fig. 2A) . EV isolations consisted of a homogeneously sized population of vesicles, many of which have morphological features of exosomes. The term exosome refers to a particular subset of vesicles that are defined by their biogenesis, and therefore we have used the term EV rather than exosomes in this report. The effect of exposure to tumor cell derived EV on cell responses to chemotherapy was then ascertained. HepG2 cells were cultured in EV-depleted medium in the presence or absence of HepG2-derived EVs for 24 h. Cells were then incubated with sorafenib, doxorubicin or camptothecin and cell viability was assessed after 48 h. Cell viability increased in an EV concentration dependent manner, with effects more prominent for doxorubicin and camptothecin than for sorafenib (Fig. 2B-D) . These observations indicate that EV can modulate cellular stress in response to chemotherapeutic agents and enhance viability.
Is the expression of long non-coding RNA altered by TGFb?
In recent studies, we identified enrichment of non-coding RNA in EV released by HCC cells. Long non-coding RNAs (lncRNAs) are being increasingly implicated in human cancers [19] , but their involvement in chemoresistance are unknown. To identify potential mediators of TGFb mediated chemosensitivity, we examined the effect of TGFb on exosomal lncRNA content using qRT-PCR. There were marked quantitative differences in several but not all lncRNA between expression in HepG2 cells and in EV derived from the same cells (Fig. 3 and Table 1 ). These data suggest that EV release of lincRNA-ROR may have specific roles in malignant cells. After 48 h, cells were collected and plated in 10 cm dishes in EV-depleted medium followed by incubation for 72 h with 0 or 10 ng/ml TGFb. EVs were then isolated from each cell. Recipient HepG2 cells were incubated with EV from each group for 48 h, and CD133 expression was assessed by flow cytometry. Bar graphs represent the mean and standard error of the permillage of CD133 positive cells from 3 separate determinants.
We identified two lncRNAs, lincRNA-ROR (linc-ROR) and linc-VLDLR that were increased in malignant hepatocytes, selectively enriched within EV with EV release further enhanced by TGFb. Together, these observations support the presence of TGFb mediated pathways for selective enrichment of these lncRNAs within EV, and their potential involvement in inter-cellular signaling in response to TGFb and as potential mediators of chemoresistance. We focused our efforts on linc-ROR because the greatest quantitative differences in EV release in response to TGFb were observed with this lncRNA, and was also highly up-regulated in malignant HepG2 cells compared with non-malignant human hepatocytes (Table 2) .
Does linc-ROR prevent chemotherapy-induced cell death?
To evaluate the potential end-target effects of linc-ROR in HCC cells, we next examined the effect of linc-ROR knockdown using siRNA on chemotherapeutic stress. Transfection of HepG2 cells with 100 nM linc-ROR-1 siRNA and linc-ROR-2 siRNA constructs reduced linc-ROR expression by 73 ± 17% and 70 ± 10% respectively after 48 h, compared with non-targeting siRNA controls. We then investigated the effect of linc-ROR knockdown and observed a significant concentration-dependent effect on cell viability in response to sorafenib, camptothecin, or doxorubicin with siRNA to linc-ROR-1 compared to controls (Fig. 4) . Further studies showed that siRNA to linc-ROR-1 increased the percentage of cells undergoing early apoptosis from 11.8% to 25.2% compared with non-targeting control siRNA during incubation with 1 lM sorafenib. siRNA to linc-ROR-1 also increased the percentage of total apoptotic cells (Fig. 5A, B) . Furthermore, caspase-3/7 activity was increased by 1.7-1.8-fold in cells transfected with siRNA to linc-ROR-1 compared to controls in HepG2 cells that were incubated with sorafenib 1 lM for 6 and 24 h (Fig. 5C) . Thus, linc-ROR can functionally modulate chemotherapy-induced apoptosis and cell survival.
To identify mechanisms by which deregulated expression of linc-ROR could contribute to tumor cell behavior, we next assessed the effect of knock-down of linc-RoR using siRNA on the mRNA expression of several genes related to liver cancer using PCR based assays. Caspase 8 and GADD45B, genes related to apoptosis and DNA damage, were increased in HepG2 cells transfected with siR-NA to linc-ROR-1 compared with control siRNA (Supplementary Table 2 ). Moreover siRNA to linc-ROR-1 did not significantly alter cell cycle progression following incubation with 10 lM of sorafenib, with an increase in percentage of cells in subG0/1 phase from 4.12% to 4.33% with siRNA to linc-ROR-1 compared with control (Fig. 5D) . As linc-ROR was reported to inhibit cell apoptosis through repression of p53 [18] , we examined p53 promoter activity (Fig. 5E ). siRNA to linc-RoR-1 significantly increased p53 activity. Furthermore, siRNA to p53 increased cell viability of HepG2 cells during doxorubicin exposure (Fig. 5F ). Altogether, these data indicate that the effects of linc-ROR could be mediated through p53 dependent signaling.
Does sorafenib increase linc-ROR expression and release within EV?
To examine the potential that linc-ROR could contribute to acquired chemoresistance, we examined the effect of chemotherapy on linc-ROR expression. First, we identified that incubation of HepG2 cells with sorafenib significantly increased linc-ROR expression compared with control cells (Fig. 6A) . Moreover, sorafenib also increased linc-ROR expression within EVs (Fig. 6B) . Together, these studies show that sorafenib increases linc-ROR expression within HCC cells and also within EV released by these cells. Linc-ROR expression was assessed by qRT-PCR in recipient HepG2 cells after incubation with varying concentrations of HepG2 derived EVs for 24 h, and noted to increase in a concentrationdependent manner supporting transfer of linc-ROR to recipient cells by EV (Fig. 6C) . In addition, incubation with EVs derived from linc-ROR knockdown HepG2 cells significantly reduced recipient cell viability during sorafenib exposure compared with EVs derived from cells transfected with control siRNA (Fig. 6D ) These data showing a correlation between resistance to chemotherapy and linc-ROR in EV's are consistent with inter-cellular transfer of linc-ROR similar to the inter-cellular transfer of microRNA by EV that we have previously shown [12, 17] .
Does linc-ROR enhance expression of tumor-initiating cells?
Tumor initiating cells with a stem-cell like phenotype may have an increased resistance to therapy. We first evaluated the effect of TGFb using limiting dilution assays of self-renewal capacity. The proportion of single cells forming spheroids was increased by TGFb (Fig. 7) . Linc-ROR has been shown to be involved in epigenetic reprogramming in embryonic stem cells [20] . We therefore examined the effect of linc-ROR on spheroid formation, and observed a reduction in spheroid formation with knockdown of linc-ROR using siRNA (Fig. 7) . In HCC, tumor initiating cells can be identified based on expression of cell surface markers such as CD133+ [21, 22] . TGFb increased expression of CD133+ cells (Fig. 8) . These data indicate that TGFb can enhance the growth of tumor initiating cells in vitro. We next examined the effect of linc-ROR on expression of CD133 expressing subpopulation using siRNA to linc-ROR-1 or NT controls. A decrease in CD133+ cells was noted with knockdown of linc-ROR compared to controls (Fig. 8) . Moreover, siRNA to linc-ROR-1 attenuated the effects of TGFb on CD133+ expression and colony formation. Thus, linc-ROR dependent expression of tumor-initiating cells may contribute to the effects of TGFb on chemoresistance in HCC.
Discussion
The poor prognosis of advanced HCC is, in part, related to the lack of effective therapeutic agents for unresectable cancers. The only agent currently approved by the FDA is sorafenib, a multikinase inhibitor that exerts antiangiogenic and anti-tumor effects by blocking multiple growth factor pathways [23] . Modest survival benefits have been reported with sorafenib in two phase III randomized trials in patients with advanced HCC [2, 24] . The use of this agent is associated with acquired chemoresistance which limits further benefit. Our findings are of importance in understanding potential mechanisms of acquired therapeutic resistance by identifying mediators and pathways by which exposure to chemotherapy modulates the local environment to limit toxicity.
Several lncRNA have been implicated in human liver diseases. A critical role for lncRNA in several diverse aspects of human disease is emerging but their specific involvement in targetable processes remains mostly unexplored. Linc-ROR is amongst the most significantly upregulated lncRNA in malignant hepatocytes. This lncRNA has been recognized to contribute to epigenetic regulators involved in pluripotency and lineage commitment [25] . Recent studies reported that linc-ROR plays a role in promoting survival in iPSCs and ESCs by preventing the activation of cellular stress pathways [20] . Our study shows that survival effects can be mediated in tumor cells following exposure to chemotherapy. The involvement of a long non-coding RNA in therapeutic responses adds to the current literature on functional capabilities of these non-coding RNA genes. The demonstration of a functional contribution to a clinically important effect provides a justification for future efforts to therapeutically target the expression of this lncRNA, through strategies similar to those proposed for targeting other non-coding RNAs [26] .
Our studies have also identified a previously unrecognized role of linc-ROR as a mediator of cell-to-cell communication through the transfer of extracellular vesicles. This represents an important mechanism by which stressed cells can signal to other cells within the local microenvironment to orchestrate responses such as activation of survival pathways. These may then result in acquired chemoresistance within tissues and contribute to loss of therapeutic effect of agents such as sorafenib.
Accumulating evidence implicates cancer stem cells in cancer resistance to therapy as well as cancer growth and spread [22] . Cancer stem cells or tumor initiating cells are thought to represent the least sensitive cell subpopulation to chemotherapy [27] . Deregulated expression and activity of TGFb has been characterized in liver cancer stem cells [28] . Targeting liver cancer stem cells is therefore an attractive strategy to improve therapeutic responses for liver cancers and other tumors. [21, 29] In order to do this, an understanding of the mechanisms by which liver cancer stem cells can mediate chemoresistance is essential. Within the liver, stem cells can be identified on the basis of expression of cell surface markers such as CD133, CD90, CD44 and EpCAM [22, 30, 31] . CD133+ liver cancer stem cells have the capacity for self-renewal and ability to differentiate, and have been identified to confer resistance to chemotherapy. Tumors arising from these cells are difficult to treat and lethal [28] . An alternate mechanism contributing to a chemoresistant phenotype in poorly differentiated tumors may involve the loss of tumor cell differentiation with acquisition of epithelial mesenchymal transition. The involvement of TGFb on this potential mechanism was not directly addressed in our study.
In conclusion, these findings provide several new mechanistic insights into acquired chemoresistance in HCC. The role of EV signaling in tumor cell responses to TGFb was evaluated and specific EV lncRNA mediators such as linc-ROR that are involved in modulation of cellular responses to chemotherapy were identified. Targeting these inter-cellular signaling mechanisms and mediators may be useful in enhancing sensitivity and improving responses to conventional therapeutic agents that are used for the treatment of HCC.
